In this regard, rGel/BLyS was recently shown to eliminate circulating cancer cells in a mouse model of disseminated BCP-ALL, but had little effect on cancer cells in the bone marrow unless these cells were mobilized using a CXCR4 antagonist [52]. This evidence concerns the gene CXCR4 and acute lymphoblastic leukemia.